Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CFTR | P13569 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | ATF1 | P18846 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850455 | 0.88 | MAPT (0.50) | MAPTCFTRMEN1KMT2AKDM4E | |
| SCHEMBL473889 | 0.88 | MAPT (0.50) | MAPTCFTRMEN1KMT2AKDM4E | |
| SCHEMBL17796812 | 0.85 | MAPT (0.45) | MAPTMEN1KMT2APOLBGAA | |
| SCHEMBL12302078 | 0.84 | MAPT (0.55) | MAPTCFTRMEN1KMT2AKDM4E | |
| SCHEMBL18795052 | 0.84 | KDM4E (0.52) | MAPTMEN1KMT2AKDM4EMAPK1 | |
| SCHEMBL21598904 | 0.82 | MAPT (0.41) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL1929528 | 0.82 | ASPH (0.42) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3780170 | 0.81 | MAPT (0.63) | MAPTCFTRMEN1KMT2AKDM4E | |
| SCHEMBL15038347 | 0.81 | MAPT (0.60) | MAPTCFTRKDM4EMAPK1NPC1 | |
| SCHEMBL1819192 | 0.81 | MAPT (0.53) | MAPTCFTRMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025096957-A1 | RAS-PI3K INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20240199589-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2005049606-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| EP-1114030-B1 | PYRIDINE KETONES USEFUL AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2004029026-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004029027-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
| US-6498125-B2 | Pyridine ketones useful as herbicides | SYNGENTA PARTICIPATIONS AG (CH) | 2002-12-24 | — | — | US | disclosed |
| US-20020016345-A1 | Pyridine ketones useful as herbicides | SYNGENTA PARTICIPATIONS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1114030-A1 | PYRIDINE KETONES USEFUL AS HERBICIDES | Syngenta Participations AG (CH) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015615-A1 | PYRIDINE KETONES USEFUL AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | MAPT 718/4885CFTR 3411/4885MEN1 3397/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | MAPT 2234/4885CFTR 3394/4885MEN1 3660/4885 |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | MAPT 2957/4885CFTR 162/4885MEN1 4086/4885 |
| US-20020016345-A1 | Pyridine ketones useful as herbicides | DDT, PDHA1, IDH2 | MAPT 3388/4885CFTR 3189/4885MEN1 4037/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAPT 3314/4885CFTR 136/4885MEN1 1966/4885 |
| US-20240199589-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MAPT 3314/4885CFTR 136/4885MEN1 1966/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | MAPT 4046/4885CFTR 52/4885MEN1 1820/4885 |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | MAPT 2519/4885CFTR 857/4885MEN1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.